Multivalent FZD4, Wnt Co-receptor, and VEGF Binding Molecules

EyeBiotech Limited filed US Patent Application US20260092125A1 claiming multivalent antibody binding molecules that simultaneously bind FZD4 receptor, LRP5 co-receptor, and VEGF, activating the Wnt/β-catenin signaling pathway for therapeutic purposes. The application (No. 19319198) covers: the antibody binding molecules themselves, nucleic acids encoding them, vectors containing those nucleic acids, and methods of using the molecules to treat conditions associated with these pathways. The CPC classification spans C07K 16/2896, C07K 16/22, C07K 16/28, and multiple C07K 2317 subclasses indicating multi-domain protein constructs.\n\nThis is a patent application publication, not a regulatory requirement or compliance obligation. No action is required by third parties. Competitors developing similar Wnt/FZD4/VEGF targeting molecules should review the claims for potential freedom-to-operate concerns once the patent issues. No compliance deadlines, penalties, or mandatory reporting requirements are associated with this publication. Entities conducting R&D in FZD4/Wnt pathway ophthalmic therapeutics should monitor the prosecution of this application through the USPTO.